Introduction
A growing number of scientific studies are focusing on identifying reliable and minimally invasive biomarkers capable of detecting Alzheimer’s disease in its earliest phases. Early diagnosis remains one of the main challenges in neurodegenerative medicine, as symptoms typically appear years after the first pathological changes in the brain. A recent study has highlighted a combination of blood-based biomarkers that may help predict cognitive decline long before clinical presentation.
The research background
Alzheimer’s disease is characterised by the accumulation of amyloid-β plaques, tau protein tangles and progressive neural damage. Traditionally, diagnosis relies on cognitive tests, cerebrospinal fluid analysis and imaging techniques such as PET. These methods, although accurate, are costly and not easily accessible. The new research approach aims to detect early molecular changes through a simple blood test, offering a more scalable solution.
The new biomarker combination
The study identified three promising biomarkers: phosphorylated tau (p-tau217), neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP). When measured together, these molecules improved the ability to distinguish individuals at high risk of developing Alzheimer’s within the following years. The simultaneous evaluation of these markers enhanced both sensitivity and specificity compared to each marker analysed individually.
Key results
Researchers analysed blood samples from individuals with normal cognition, mild cognitive impairment and confirmed Alzheimer’s disease. Elevated levels of p-tau217 were strongly associated with early amyloid pathology, while increases in NfL reflected neuronal injury. GFAP levels indicated early astrocyte activation, a process thought to precede cognitive symptoms. Participants with abnormal values in all three markers were significantly more likely to show cognitive decline in long-term follow-up.
Clinical implications
If validated in larger populations, these biomarkers could support routine screening in primary care and help identify individuals who may benefit from early interventions or monitoring. This is particularly relevant as new disease-modifying treatments require administration before substantial neurodegeneration occurs. Blood-based biomarkers could also reduce reliance on invasive lumbar punctures and costly imaging.
Limitations and future research
Although results are promising, researchers underline the need for multi-centre studies involving diverse populations. It remains essential to determine how these biomarkers behave across different stages of the disease and in individuals with overlapping neurodegenerative conditions. Further investigations will also focus on integrating biomarker testing into clinical workflows and establishing reference values for different age groups.
Conclusion
The identification of a reliable panel of blood biomarkers marks an important step toward earlier and more accessible diagnosis of Alzheimer’s disease. Continued research will clarify how these markers can be used in practice to improve patient outcomes and guide therapeutic decisions.
Source: Source
Copyright © Tutti i diritti sono riservati – Salute33